Clinical trial
Effect of Insulin Glargine and Lixisenatide Versus Insulin Glargine on Brain Insulin Sensitivity in Patients With Type 2 Diabetes
NCT03881995 is registered in ClinicalTrials.gov with University Hospital Tuebingen as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Effect of Insulin Glargine and Lixisenatide Versus Insulin Glargine on Brain Insulin Sensitivity in Patients With Type 2 Diabetes
- Lead sponsor
- University Hospital Tuebingen
- Phase
- Phase 4
- Overall status
- Terminated
- Start date
- March 18, 2019
- Completion date
- June 29, 2020
- Enrollment
- 1 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.